Vietnam Produces Test Batch Of Sputnik V Vaccine: Russia


The test batch of Sputnik V was produced in partnership with Vietnam’s state-owned pharma firm Vabiotech, said Russian Direct Investment Fund.

Vietnam Produces Test Batch Of Sputnik V Vaccine: Russia

First samples of Vietnam’s Sputnik V batch will be sent to Russia for quality control, RDIF said (File)


Russia announced Wednesday that a batch of its Sputnik V coronavirus vaccine was produced for the first time in Vietnam, which is battling a new wave of COVID-19 infections. The test batch was produced in partnership with Vietnam’s state-owned pharmaceutical company Vabiotech, the Russian Direct Investment Fund (RDIF), which financially backed Sputnik V, said in a statement.

The first samples from the batch will be shipped to the vaccine’s developer — the Gamaleya Centre in Moscow — for quality control, the RDIF added. “RDIF and Vabiotech are actively cooperating in the technology transfer process to provide easier access to Sputnik V for the population of Vietnam,” the fund’s CEO Kirill Dmitriyev said in the statement.

The president of Vabiotech, Dat Tuan Do, welcomed the announcement saying it “will help provide quality and affordable” vaccines to Vietnam and other countries in the region.

Vietnam has recently faced a surge in new infections with the government putting about a third of the country’s 100 million people under stay-at-home orders to contain the outbreak. The Southeast Asian country has been slow to procure and administer vaccines, with just 4.3 million doses given as of Monday.

Russia registered Sputnik V last August ahead of large-scale clinical trials, prompting concern among experts over the fast-tracked process. It has since been declared safe and over 90 percent effective in a report published by leading medical journal The Lancet, restoring confidence in Russia’s jab.

The RDIF has signed production agreements with several countries, including India, which is expected to produce several hundred million doses per year. The RDIF says its two-dose vaccine has been approved in 68 countries and that it has applied for registration in the European Union.

(Except for the headline, this story has not been edited by our staff and is published from a syndicated feed.)


Please enter your comment!
Please enter your name here

All the data shown above will be stored by on At any point of time, you can contact us and select the data you wish to anonymise or delete so it cannot be linked to your email address any longer. When your data is anonymised or deleted, you will receive an email confirmation. We also use cookies and/or similar technologies to analyse customer behaviour, administer the website, track users' movements, and to collect information about users. This is done in order to personalise and enhance your experience with us. Click here to read our Cookie Policy.